Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04409327
Recruitment Status : Terminated (Insufficient accrual rate)
First Posted : June 1, 2020
Last Update Posted : February 10, 2021
Sponsor:
Information provided by (Responsible Party):
Restorbio Inc.

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Terminated
Actual Primary Completion Date : December 27, 2020
Actual Study Completion Date : January 24, 2021
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 June 1, 2021
June 7, 2021 Submission with QC Comments